BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gregor J, Radilová K, Brynda J, Fanfrlík J, Konvalinka J, Kožíšek M. Structural and Thermodynamic Analysis of the Resistance Development to Pimodivir (VX-787), the Clinical Inhibitor of Cap Binding to PB2 Subunit of Influenza A Polymerase. Molecules 2021;26:1007. [PMID: 33673017 DOI: 10.3390/molecules26041007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Chen W, Shao J, Ying Z, Du Y, Yu Y. Approaches for discovery of small-molecular antivirals targeting to influenza A virus PB2 subunit. Drug Discov Today 2022:S1359-6446(22)00085-X. [PMID: 35247593 DOI: 10.1016/j.drudis.2022.02.024] [Reference Citation Analysis]
2 Soh YQS, Malone KD, Eguia RT, Bloom JD. Comprehensive Profiling of Mutations to Influenza Virus PB2 That Confer Resistance to the Cap-Binding Inhibitor Pimodivir. Viruses 2021;13:1196. [PMID: 34206520 DOI: 10.3390/v13071196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yeo JY, Gan SK. Peering into Avian Influenza A(H5N8) for a Framework towards Pandemic Preparedness. Viruses 2021;13:2276. [PMID: 34835082 DOI: 10.3390/v13112276] [Reference Citation Analysis]
4 Denel-bobrowska M, Olejniczak AB. Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020). European Journal of Medicinal Chemistry 2022;231:114136. [DOI: 10.1016/j.ejmech.2022.114136] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 O'Driscoll LS, Martin-Loeches I. Management of Severe Influenza. Semin Respir Crit Care Med 2021;42:771-87. [PMID: 34918320 DOI: 10.1055/s-0041-1735491] [Reference Citation Analysis]